A primer on HELIOS-B, an enormous stock-moving event for Alnylam Pharmaceuticals

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

The outcome of the HELIOS-B study — expected at the end of June or early July — is an enormous stock-moving event for Alnylam Pharmaceuticals. Billions of dollars in potential revenue — sufficient to power Alnylam into profitability — are on the line.

The results will also impact competitors, including BridgeBio Pharma and Ionis Pharmaceuticals.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In